CVM vs. CRDL, VIGL, PLX, ZURA, ALVR, OTLK, BCAB, ELUT, TIL, and ALGS
Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Cardiol Therapeutics (CRDL), Vigil Neuroscience (VIGL), Protalix BioTherapeutics (PLX), Zura Bio (ZURA), AlloVir (ALVR), Outlook Therapeutics (OTLK), BioAtla (BCAB), Elutia (ELUT), Instil Bio (TIL), and Aligos Therapeutics (ALGS). These companies are all part of the "biological products, except diagnostic" industry.
Cardiol Therapeutics (NASDAQ:CRDL) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
Cardiol Therapeutics received 13 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 48.15% of users gave Cardiol Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
CEL-SCI's return on equity of -64.56% beat Cardiol Therapeutics' return on equity.
Cardiol Therapeutics has higher revenue and earnings than CEL-SCI. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.
Cardiol Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, CEL-SCI has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
Cardiol Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 65.75%. Given CEL-SCI's higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than CEL-SCI.
In the previous week, Cardiol Therapeutics had 8 more articles in the media than CEL-SCI. MarketBeat recorded 9 mentions for Cardiol Therapeutics and 1 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.98 beat Cardiol Therapeutics' score of 0.48 indicating that Cardiol Therapeutics is being referred to more favorably in the media.
12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 16.2% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Cardiol Therapeutics beats CEL-SCI on 12 of the 15 factors compared between the two stocks.
Get CEL-SCI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools